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HCT h e m a to c r i t
LORCA L a s e r -a s s is te d  O p tic a l  R o ta t io n a l C e ll  A n a ly z e r
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RBC re d  b lo o d  ce ll
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1. INTRODUCTION
Cardiovascular diseases are the most frequent causes of morbidity and 
mortality in the developed countries. In spite of the extended research on this field, 
there still remained obscure parts in the pathomechanism of these diseases. 
Investigations explored the role of vascular wall, cellular interactions, and many of 
the underlying biochemical processes. Less attention was paid to the properties of the 
circulating blood and even less to the relationship of these factors and oxygen free 
radicals.
Coronary artery disease (CAD), the stenotic lesion of one or more coronary 
branches is the most frequent type of ischemic heart disease (IHD). In the 
development of IHD several risk factors may play a role, which can influence each 
other. While the role of “classic” risk factors (e.g. smoking, hypertension, 
hypercholesterolemia, diabetes, etc.) has been well known for a long time, the 
importance of hemorheologic parameters in the development of coronary artery 
disease has been accepted only for the last two decades.
Coronary vessel system is a special part of the circulation. There is a 
continuous change in blood flow, perfusion pressure, and shear rate due to the 
cardiac cycle, moreover, the narrowest capillaries of the body can be found in the 
myocardium (diameter can be as small as 3-5 pm, several micrometers smaller 
comparing to that of red blood cells). Therefore the role of rheological alterations 
can be of higher importance than in other parts of the circulatory system. In several 
studies hemorheological parameters were proved to be primary cardiovascular risk 
factors (Framingham Study, Nortwick Park Study, Monica Project, Edinburgh Artery 
Study).
Acute ischemic coronary syndrome (AICS) is caused by the acute disorder in 
the blood supply of the myocardium caused by the sudden decline of coronary blood 
flow or by the sudden raise of myocardial oxygen demand. Mortality and morbidity 
of patients with this syndrome are substantial, therefore AICS has considerable 
medical, social and economic importance all over the world. Prevention and 
elimination of risk factors are the most powerful ways to reduce the mortality and 
morbidity of this syndrome. As previously mentioned, classical risk factors of
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cardiovascular diseases are well known and many of them could be prevented. 
Previous studies have already confirmed that hemorheological parameters also could 
have determining role in the development and severity of AICS. Experimental 
evidences underline that hemorheological alterations observed in acute myocardial 
infarction (AMI) are also involved in the decreased perfusion of the damaged area 
and the extension of the necrotic regions. Some of the rheological parameters 
(e.g. plasma fibrinogen level, white blood cell count) known as “non-classic” risk 
factors have been recently clarified to have determining role in the prognosis of 
patients after AMI. Although several studies examined a part of rheological 
parameters in AICS, few of them examined all of these parameters simultaneously. 
Thus further investigations should reveal which hemorheological factors have 
significant role in the development of CAD or AICS. The examination of these 
parameters can help to modify them favorably in the future, which can be important 
in the prevention and treatment of cardiovascular diseases.
Elevated plasma fibrinogen concentration is associated with increased 
frequency of coronary heart disease and stroke. It was proven as a primary risk factor 
for cardiovascular and cerebrovascular disease in healthy individuals and a risk 
factor for death or recurrence of myocardial ischemia in patients with a previous 
coronary event. Nevertheless, the numerous studies investigating the role of 
fibrinogen in red blood cell (RBC) aggregation, the mechanism of its action has not 
fully been elucidated. Although fibrinogen has a determining rote, several other 
plasma factors also have significant influence on RBC aggregation.
Increased RBC aggregation has a negative effect on the flow dynamics of 
blood and it is known to be associated with many clinical states (e.g. ischemic heart 
disease, acute myocardial infarction, cardiogenic pulmonary edema, thromboembolic 
states, renal failure, diabetes mellitus, venous thrombosis). The generally accepted 
theory for RBC aggregation is the bridging hypothesis, which supposes that RBC 
aggregation is due to the bridging between neighboring cells by specific plasma 
proteins (e.g. fibrinogen, large molecular weight globulins) and can also be induced 
by large macromolecules such as high molecular weight dextrans and other polymers. 
On the other hand, a few reports have questioned this hypothesis and proposed a 
thermodynamic model based on polymer/proteln depletion from the intercellular
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contact zone. It is important to know that RBC aggregation is a dynamic process and 
thus represents a balance between forces of aggregation and disaggregation 
(e.g. mechanical shear, electrostatic repulsion between cells). Thus, in general, the 
aggregation process depends on the properties of the erythrocytes as well as the 
mechanical and physicochemical characteristics of their environment.
Because of the several different methods used to determine RBC aggregation 
in different laboratories, the standardization of aggregation measurements is 
important for getting comparable results. As these measurements do not completely 
reflect to the real in vivo situation, comparison and/or parallel measurements by 
different methods can characterize better the different aspects of this complex 
process.
Oxygen free radicals are highly reactive chemical species generated in 
biological systems during numerous physiological and pathophysiological processes. 
In physiological circumstances they play a role in cellular metabolism and cellular 
defense systems, on the other hand, large amount of oxygen free radicals is highly 
toxic for tissues and cells, because they can oxidatively modify and damage a variety 
of biological systems (e.g. cellular proteins, nucleic acids, carbohydrates, and lipids). 
Although cells have various defense systems against free radical damages including 
scavenger enzymes (e.g. superoxide dismutase, catalase, glutathion peroxidase) and 
nonenzymatic molecules (e.g. glutathion, ubiquinone [coenzyme Q], ascorbate, 
vitamin G), in case of impaired antioxidant defense or increased production of 
oxygen free radicals, these reactive agents can take part in formation of serious 
disorders. They are thought to be involved in a wide range of diseases such as 
atherosclerosis, ischemia-reperfusion injury, diabetes mellitus, inflammatory 
diseases and immunological disorders.
Because o f the wide range o f diseases involving oxygen free radical damages, 
scavenging these radicals should be considered as a basically important therapeutic 
approach.
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2. AIMS OF THE INVESTIGATIONS
1. Our purpose was to examine the antioxidant properties of a novel, 
experimental antlarrhythmlc-cardloprotective compound, H-2545 and its metabolite 
H-2954. Besides these new agents we aimed to study the antioxidant capacity of 
several clinically used cardiovascular drugs.
2. The pyrroline ring in the molecular structure of H-2545 was supposed to be 
responsible at least partially for the antioxidant capacity. To confirm this theory 
modification of the mexiletine and trimetazidine molecules with pyrroline ring was 
planned to be investigated. We wanted to compare the antioxidant properties of the 
new compounds and the modified drugs to those of the clinically used cardiovascular 
drugs.
3. Plasma fibrinogen concentration is an important risk factor of 
cardiovascular diseases. The role of fibrinogen concentration as a risk factor can be 
due to at least partially to its effect on hemorheological parameters. To challenge this 
theory the effects of different fibrinogen concentrations on the microrheological 
parameters, especially on the RBC aggregation were tended to be investigated. We 
wanted to study the effect of fibrinogen concentration on red blood cell aggregation 
both in vitro and in vivo. Our purpose was to compare two different RBC 
aggregation measurement methods to each other and to examine the relationship 
between RBC aggregation indices measured by these methods and plasma fibrinogen 
concentration.
4. To reveal the role of the rheological disorders in acute ischemic coronary 
syndromes we aimed to examine hemorheological parameters and platelet 
aggregation in patients with AICS. Besides the comparison of these parameters in 
patients with AICS and healthy subjects we planned the follow-up of their changes 
after discharge.
5. We wanted to estimate the biological effect of routine antiplatelet therapy 
in our patients. We intended to use platelet aggregometer in order to determine the 
level of platelet aggregation induced by different inductor agents.
6
3. MATERIALS AND METHODS
3.1. Antioxidant properties of different cardiovascular drugs
3.1.1. Sample preparation
Venous blood samples (40 ml) were taken from the antecubital vein of six 
healthy male volunteers into Vacutainer tubes containing sodium heparin as an 
anticoagulant. Blood samples were centrifuged at 2500 g for 10 minutes, then plasma 
and buffy coat were removed. Red cell suspensions were washed twice in phosphate 
buffered saline (PBS) (pH: 7.4, osmolality: 300 mOsm, glucose: 10 mM). After the 
last centrifugation supernatant was removed and RBCs were resuspended in PBS. 
The hematocrit of red blood cell suspension was adjusted to 20 % and suspensions 
were incubated with 1 mM phenazine methosulphate (PMS) at 37 °C, for 
120 minutes. A cardiovascular drug was also added to the incubating medium at two 
concentrations in “treated” tubes: maximum serum concentration used in vivo, and 
five times higher concentration (experimental agents were examined also in other 
concentrations). PMS and drugs were not added to control samples. After incubation 
blood samples were centrifuged, supernatant was removed and hematocrit was 
adjusted to 10 % using PBS. Red blood cell filterability of these suspensions and 
potassium concentration of the supernatant were determined. During sample 
preparation microhematocrit centrifuge (Hemofuge, Heraeus Instr., Germany) was 
used to determine the hematocrit of suspensions.
3.1.2. Examined drugs
Carvedilol was provided by Boehringer Mannheim (Mannheim, Germany), the 
other clinically used drugs (procainamide, mexiletine, propafenon, metoprolol, 
timolol, sotalol, amiodarone, verapamil, nifedipine, trimetazidine and trolox) were 
purchased from Aldrich Chemical Co., Inc. (Milwaukee, USA). Experimental drug 
(H-2545), its metabolite (H-2954), trimetazidine, modified mexiletine (HO-2434), its 
metabolite (HO-2433) and modified trimetazidine (H-2921R) were synthesized in the 
Institute of Organic and Medicinal Chemistry of the University o f Pécs.
7
3.1.3. Measurement o f RBCfiltration
Red blood cell filterability was measured by Carat FT-1 Filtrometer 
(CARAT Ltd., Hungary) using St. George's technique. In this filtrometer RBC 
suspension flows through a Nucleopore filter with 5 pm diameter pores. Filtration 
rate is measured at four pairs of light sources and detectors. The apparatus is 
interfaced to a computer, which automatically analyses sequential flow rates and thus 
distinguishes between cell transit time (relative cell transit time - RCTT) and pore 
clogging rate. Filtration pressure was set to 4 cm of water in our experiments. All 
measurements were carried out at room temperature (22 ± 1 °C) and were repeated 
three times at each sample.
Results were expressed in percent of decrease of PMS-induced increase in
RCTT:
-  ( R C T T p m s  " RCTTpM S+cardiovasculardnig) /  (R C T T p M S  “ RCTTControl) * 100.
3. L 4. Measurement o f potassium concentration
Potassium concentration of the supernatant was measured by OMSZOV 
OE851 digital flame photometer (with propane-butane gas burner) (OMSZOV, 
Hungary) and lithium base solution was used.
Results were expressed in percent of decrease of PMS-induced potassium 
leaking due to drugs:
“ (K. PMS “ K  PMS+eardiovascular drug) !  ( K  PMS " K  Control) x  1 0 0 .
3.2. Relationship between fibrinogen concentration and RBC aggregation 
measured by different methods
3.2.1. Sample preparation
To determine the effect of fibrinogen concentration on RBC aggregation, 
measurements were performed in fibrinogen solutions. Blood samples were drawn 
from the antecubital vein of healthy adult volunteers into EDTA (1.5 mg/ml) and all 
measurements were performed within three hours after venesection. PBS was 
prepared as follows: 0.030 M KH2PO4 + Na2HPC>4, 0.122 M NaCl; pH -  7.4,
295 ± 5 mOsmol/kg. Fibrinogen (2 % lyophilized human fibrinogen; American 
Diagnostica Inc., USA) was dissolved in PBS. Red blood cells were separated from 
whole blood via 2000 g centrifugation for 10 minutes, then, subsequently, plasma 
and buffy coat were removed. RBCs were washed three times, twice in PBS and third 
time in fibrinogen solution; residual portions of the buffy coat were discarded after 
each centrifugation. The washed RBCs were then resuspended in fibrinogen solutions 
(0.5, 0.6, 0.75, 0.9 and 1.0 mg/ml concentration, respectively) at a hematocrit of 
41.0 ± 0.3 % for aggregation measurements in Myrenne aggregometer. All 
preparations and measurements were carried out at room temperature (22 ± 1°C).
For the comparative RBC aggregation measurements in whole blood, sixty two 
blood samples from subjects (including healthy volunteers, patients with ischemic 
heart disease and diabetes mellitus, mean age: 49.9 ± 16.7 years; 37 males, 
25 females) were analyzed in Myrenne MA-1 RBC aggregometer and LORCA (laser- 
assisted optical rotational cell analyzer) aggregometer. The blood was drawn from 
the antecubital vein into Vacutainer tube containing lithium heparin (143 IU / 4.5 ml) 
and all measurements were performed at the native hematocrit of the samples within 
two hours after venesection. Hematocrit was measured by using microhematocrit 
centrifuge. Fibrinogen concentration was determined by Clauss’s method. 
Temperature in LORCA was adjusted to 37 °C, all other preparations and 
measurements were carried out at room temperature (22 ± 1 °C).
3.2.2. Aggregation measurements
RBC aggregation was measured in two instruments: Myrenne and LORCA 
aggregometers (blood samples were taken from the same tube).
1/ Myrenne aggregometer (Model MA-1 Aggregometer, Myrenne GmbH, 
Germany) employs the light transmission method of Schmid-Schönbein et al. through 
a transparent cone-plate shearing instrument. The principle of this technique is the 
increase of light transmission through a red cell suspension, which occurs when 
individual cells aggregate into rouleaux or rouleaux-rouleaux complexes; gaps in the 
suspending medium between the aggregates allow more light to pass through the 
RBC suspension. This aggregometer has two modes of operation: M and Ml. For 
both modes blood sample (30 pi) is first sheared at 600 s'1 to disperse all pre-existing
9
aggregates, then shear rate decreases rapidly to zero (M mode) or low shear 
(3 s'1: Ml mode). The extent of aggregation is characterized by the aggregation index 
(AIm, AImi), calculated from the surface area below the light intensity curve in a 10 s 
period of time.
2/ Aggregation measurements by LORCA aggregometer (R&R Mechatronics, 
Netherlands) are based on the detection of laser back-scattering from the sheared 
(disaggregated), then unsheared (aggregating) blood, performed in a computer- 
assisted system. Blood samples (1 ml of oxygenated blood) are injected into the gap 
between the outer cylinder “cup” and the inner cylinder “bob” of LORCA. During 
the measurement the cup is driven by a computer controlled stepper motor and 
temperature is adjusted to 37 °C. Blood sample is sheared at 400 s*1; then shear rate 
decreases rapidly to zero. Back-scattering data are evaluated by the computer and the 
aggregation index (A1l) is calculated from the syllectogram (light scatter vs. time 
curve during a 120 s period) on the basis that there is less light back-scattered from 
aggregating red cells.
Data were evaluated as means ± S.E.M. (standard error of mean) by Student’s 
t test and correlation analysis.
3.3. Hemorbeological parameters in patients with acute ischemic coronary 
syndromes
3.3.1. Study population
12S patients with AICS (72 males and 53 females; mean age: 65 ± 12 years) 
and 68 healthy persons (30 males and 38 females; mean age: 36 ± 6 years) were 
investigated in a prospective study. All of the patients were admitted to our coronary 
care unit with acute ischemic heart symptoms and routine examinations (ECG, 
myocardial enzymes) proved the AICS in each case. 57 patients had significant 
ST elevation, 55 patients had ST depression or no ST deviation and 13 patients had 
left bundle branch block or ventricular pacemaker rhythm on admission. 45 patients 
were on antiplatelet therapy on admission, 34 of them took ASA (average dose: 
140mg/day), 4 of them took 100 mg ASA and 500 mg ticlopidine, 1 patient took 
325 mg ASA and 500 mg ticlopidine, 2 patients took 100 mg ASA and 75 mg
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clopidogrel, 2 patients took 500 mg ticlopidine, 1 patient took 250 mg ticlopidine 
and 1 patient took 75 mg clopidogrel daily. After admission thrombolysis was 
performed in 21 cases and percutaneous coronary intervention in 20 patients. Almost 
all the patients were on subcutaneous low molecular weight heparins and 
i.v. nitroglycerin during the acute phase. 29 of them received i.v. platelet Ilb/llla 
receptor blocker. 120 patients were on antiplatelet therapy at discharge, 84 o f them 
took ASA (average dose; 190 mg/day), 15 of them took 100 mg ASA and 500 .mg 
ticlopidine, 7 patients took 325 mg ASA and 500 mg ticlopidine, 5 patients took 
100 mg ASA and 75 mg clopidogrel, 3 patients took 500 mg ticlopidine and 6 patient 
took 75 mg clopidogrel daily. There was no relevant change in their medication after 
discharge.
Blood samples were taken from the cubital vein, and routine blood chemistry 
and hemorheological parameters - hematocrit, plasma fibrinogen level, plasma and 
whole blood viscosity, RBC aggregation, RBC deformability and platelet aggregation 
- were determined.
3.3.2. Hemorheological measurements 
Hematocrit
Venous blood collected into lithium-heparin coated Vacutainer tubes was used 
to determine hematocrit. Hematocrit was measured by centrifuging hematocrit 
capillaries (80 pi, containing heparin) at 12000 rpm for five minutes in 
microhematocrit centrifuge (Hemofuge, Heraeus Instr., Germany). Measurements 
were performed at room temperature (22 ± 1 °C).
Plasma and whole blood viscosity
Venous blood samples were collected into lithium-heparin coated Vacutainer 
tubes for viscosity measurements. Plasma was prepared by centrifuging one tube of 
blood at 1500 g for ten minutes. Plasma and whole blood viscosities were determined 
in Hevimet 40 capillary viscosimeter (Hemorex Ltd., Hungary). 0.5 - 0.5 ml of 
plasma or whole blood was injected into the capillary tube of the device. In this 
viscosimeter the flow of the fluid is detected optoelectronically along the capillary
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tube and a flow curve is drawn. Shear rate and shear stress are calculated from this 
curve by a computer program. Viscosity values are determined as a function of these 
parameters according to Casson's principle.
For the presentation of our results, apparent whole blood viscosity values 
calculated at 90 s '1 shear rate are given. Corrected whole blood viscosity was 
calculated with a mathematical formula according to Mátrai et al. In this formula 
apparent whole blood viscosity value at 90 s*1 shear rate (WBVhct) is used and 
correction is made to 40 % hematocrit:
WBV40% / PV = (WBVhct / PV)40* ' HCT
Measurements were carried out at 37 °C within two hours after venepuncture. 
Plasma fibrinogen
4.5 ml blood sample was drawn into a Vacutainer tube containing sodium 
citrate (0.129 M, 1:10 dilution) and plasma fibrinogen concentration was determined 
by using Gauss’s method.
RBC aggregation
RBC aggregation measurements were carried out from venous blood samples • 
collected into lithium-heparin coated Vacutainer tubes by Myrenne aggregometer 
(Model MA-1 Aggregometer, Myrenne GmbH, Germany) according to the previously 
described method. Measurements were performed at room temperature (22 ± 1 °C) 
and were carried out within two hours.
Measurement o f RBC filtration
Red blood cell filterability was measured by Carat FT-1 filtrometer 
(CARAT Ltd., Hungary) according to the previously mentioned method. 




Spontaneous, epinephrine-, ADP- and collagen-induced aggregation of 
platelets was analyzed. Blood was taken into tubes containing sodium citrate. 
Samples were centrifuged at 150 g for 10 minutes to produce platelet rich plasma 
(PRP), which was carefully removed for measurement; and then centrifuged further 
at 2500 g for 10 minutes to get platelet poor plasma (PPP). 450 pi PRP was measured 
against 450 pi PPP to determine spontaneous platelet aggregation. 50 pi of ADP 
(2 pM, 5 pM and 10 pM), epinephrine (5 pM, 10 pM and 15 pM) or collagen 
(2 pg/ml) was added to PRP so as to measure induced platelet aggregation. Platelet 
aggregation was measured in Carat TX4 platelet aggregometer (Carat Ltd., Hungary). 
The principle of its technique is similar to that of used by Myrenne aggregometer: 
the increase of light transmission through a platelet suspension, which occurs when 
individual platelets aggregate; gaps in the suspending medium between the 
aggregates allow more light to pass through the suspension. Activation of platelets, 
hereby platelet aggregation can be induced by different agents. To eliminate the 
differences between the absolute light transmission of different samples, PPP is used 
to determine the base intensity of the plasma and platelet aggregation indices are 
calculated with the ratio between the light transmission of PPP and PRP.
Antiplatelet medication was considered to be effective if the aggregation 
indices were lower than the range of untreated persons with 95 % confidence 
intervals. Measurements were carried out at 37 °C within two hours after 
venepuncture.
4. RESULTS AND CONCLUSIONS
4.1. Antioxidant properties of different cardiovascular drugs
The filterability of RBCs treated with PMS was reduced significantly 
compared to control samples, which referred to the increased rigidity of cells. 
Similarly to changes of RBC filtration, the potassium concentration of the 
supernatant was significantly higher in PMS treated samples, which again proved the 
RBC membrane damage.
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H-2545 provided highly significant protection against both PMS-induced 
RCTT increase and potassium leaking. Moreover, H-2545 showed the best scavenger 
activity at the same concentration, which had the best antiarrhythmic effect without 
any side effects. The metabolite of the experimental agent, H-2954 also had 
significant antioxidant activity, however this was better at higher concentration. As 
this metabolite also has significant antioxidant activity, H-2S4S can eliminate free 
radicals in two steps: in the first step the amino compound is oxidized to the 
hydroxylamine and in the second step to the nitroxide form, so the scavenger activity 
of the drug and the metabolite is added up.
All the examined class I antiarrhythmic drugs (procainamide, inexiletine and 
propafenon) had only a weak, but in some concentrations significant antioxidant 
effect, which was almost equal in the different subclasses. Although their scavenging 
activity was statistically significant, it is questionable if this effect can also be 
clinically significant.
Among the examined p-blockers (metoprolol, carvedilol, timolol) carvedilol 
had the strongest antioxidant effect, which was significantly higher comparing to 
those of the other drugs in this group. Metoprolol and timolol also showed a mild, 
but statistically significant antioxidant property. The significant antioxidant property 
of p-blockers in our study may imply a potential therapeutic significance in addition 
to their well-known effects.
In class III, sotalol had similar protective effect to RCTT and potassium 
leaking as p-blockers, while amiodarone did not show any antioxidant property. 
Although sotalol belongs to class III, it has strong p-blocker properties, which can 
explain our results.
Among Ca-channel blockers verapamil provided highly significant protection 
against PMS-induced damages. The other examined Ca-channel blocker, nifedipine 
did not have a significant scavenger effect. Ca antagonists are believed to be 
lipophilic to various degrees and would concentrate presumably in the lipid domains 
of the phospholipid membranes. Oxygen free radicals generate lipid peroxidation in 
these membranes, which increases membrane and thus cellular rigidity and disturbs 
the barrier and transport function of the cell membrane. A Ca-channel blocker with 
antioxidant property may prevent free radical damages in membranes.
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Trimetazidine was able to protect RBCs from the effect of PMS only at higher 
concentration. Perhaps the lack of lipophilic property accounts for this result, as 
trimetazidine does not accumulate in plasma membrane, which is one of the main 
determining factors of RBC deformability.
Comparing to the examined cardiovascular drugs, Trolox (water-soluble form 
of vitamin E) provided more significant protection against oxidative damage. The 
scavenger effects of the new experimental agents reached or even exceeded the 
scavenger capacity of this well-known antioxidant substance. Moreover H-2545 
showed significantly higher antioxidant property in therapeutic concentration than 
any of the examined drugs.
The scavenger effect of the modified drugs (mexiletine and trimetazidine 
derivatives with pyrrolin ring) was improved significantly after the modification. 
These agents showed more than three times higher protective effect against PMS- 
induced damages than the basic molecules. These results suggest that the pyrroline 
ring is responsible for a significant part of the antioxidant properties. The scavenger 
properties of the metabolite of the modified mexiletine were also investigated. 
Similarly to the metabolite of H-2545, HO-2433 also has antioxidant capacity, which 
suggests that drugs modified with the pyrroline ring can eliminate free radicals in 
two steps.
4.2 Relationship between fibrinogen concentration and RBC aggregation 
measured by different methods
Analyzing RBC aggregation indices in fibrinogen solutions, an increase of 
RBC aggregation measured by Myrenne MA-1 aggregometer could be noted at higher 
fibrinogen concentrations. Although correlation between fibrinogen concentration 
and RBC aggregation was significant, above a certain fibrinogen concentration 
(0.9 g/1) aggregation index did not show a further increase in vitro. Excluding 
samples with that high fibrinogen concentration the correlation became even stronger 
and the correlation coefficient was higher. These results may imply that above a 
certain level no more fibrinogen binding could occur at the surface of the cell.
Analyzing all the human whole blood samples, there was a significant 
relationship between plasma fibrinogen and AIl, however, correlation between
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fibrinogen and AIm or AImi could not be proved. There was no significant correlation 
between AIl and AIm, whereas correlation of AIl and AImi was significant. Further 
analysis based on the scatter plot diagram revealed that in human samples (similarly 
to the in vitro measurements) there is no further increase in the aggregation index 
above a certain fibrinogen concentration (4.5 g/1). After excluding samples with the 
above mentioned high fibrinogen concentration, significant correlation could be 
calculated between fibrinogen concentration, AIl and AImi. Using the data of these 
samples only, significant correlation could be found not only between AIl vs. AImi, 
but also between AIl vs. AIm- The lower in vitro fibrinogen concentration at the 
plateau phase reflects to that in vivo other factors beside fibrinogen play an 
important part in the aggregation / disaggregation process.
4.3. Hemorheological parameters in patients with acute ischemic coronary 
syndromes
Almost all the measured hemorheological parameters (hematocrit, plasma 
fibrinogen concentration, white blood cell count, plasma and whole blood viscosity, 
red blood cell aggregation and deformability) were significantly worse in patients 
with A1CS at admission than in control subjects. Although, RBC aggregation index 
measured in M mode was not statistically different in the two groups that measured 
in Ml mode was significantly higher in patients than in control subjects.
During the hospital phase hematocrit values of patients with A1CS showed a 
gradual decrease, which became significant after six days and was associated by a 
slight decrease of whole blood viscosity. On the first two days plasma fibrinogen, 
C-reactive protein and white blood cell count showed a significant elevation. As 
plasma fibrinogen is a major determinant of plasma viscosity, its elevation was 
associated with the elevation of plasma viscosity. During the hospital phase both of 
the examined microrheological parameters (RBC aggregation and filtration) were 
found prominently worse at admission and on day two. While some of the other 
hemorheological parameters decreased considerably by day 6, plasma fibrinogen and 
plasma viscosity still remained high, moreover, further elevation was noticeable, 
which calls the attention to the remained hemorheological risk at discharge. The 
elevation in fibrinogen might increase the risk of repeated acute coronary events,
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since fibrinogen plays a central role in platelet and erythrocyte aggregation and is 
one of the main determinants of plasma and whole blood viscosity.
Hematocrit was elevated at the one-month sampling in correspondence with 
whole blood viscosity and they showed further elevation at the six-month and one- 
year examination. CRP values returned to the normal range after discharge, and 
remained there during the follow-up. White blood cell counts decreased significantly 
after the acute phase of the disease, but they were slight above than those of control 
subjects during the whole follow-up. Although plasma fibrinogen concentration 
decreased significantly after discharge and was moderately lower than the admission 
value, plasma viscosity did not show the same pattern during the follow-up. Among 
the microrheological parameters RBC filterability remained in the pathologic range 
during the entire follow-up period. Though a few hemorheological parameters 
decreased after the acute phase of the disease, several of them remained significantly 
higher than those of control subjects and some of them showed even an increase 
during the follow-up period. These alterations should draw attention to the 
rheological risk of these patients.
In this study we also examined the efficacy of the commonly used antiplatelet 
therapy. Our present aim w as to estimate the effect of the routine therapy; the results 
of platelet aggregation measurements were not yet considered in the therapy after 
discharge. Although almost all the examined patients had some cardiovascular risk 
factors before the acute coronary event, only one third of them were on antiplatelet 
drugs regularly and this was measured to be efficient in less than half of the treated 
subjects. During the hospital phase the efficacy of platelet aggregation inhibitory 
therapy improved significantly and further enhancement could be seen after 
discharge. Despite of this improvement, the ratio of inadequately treated patients was 
still almost 30 % at each follow-up visits. These results show the failure of routine 
antiplatelet medication and support the importance of a guided therapy.
17
5. SUMMARY
1. We found that the novel, experimental antiarrhythmic-cardioprotective drug 
had highly significant antioxidant capacity. This property is presumably due to the 
molecular segment containing the pyrroline ring, hence the scavenger capacity of a 
clinically used antiarrhythmic drug was significantly improved by the modification 
with this segment. We could show that some of the clinically used cardiovascular 
drugs had significant antioxidant effects that could be useful in the clinical practice.
2. Our study showed that both Myrenne and LORCA red blood cell 
aggregometers were easily applicable in the clinical practice. Although LORCA 
aggregometer needs larger amount of blood, it seems to provide more precise 
information on red blood cell aggregation presumably due to its more standardized 
conditions. Further investigations in large population are needed to standardize these 
techniques and clarify the clinical significance of these measurements.
3. In a study we investigated and followed-up the hemorheological parameters 
in patients with acute ischemic coronary syndrome and estimated the efficacy of 
routine antiplatelet therapy. Both macrorheological and microrheological parameters 
were found significantly worse in patients than in healthy subjects. Moreover, some 
of these parameters showed further impairment after the acute event. Antiplatelet 
therapy was efficient in less than half of the treated patients at admission; and 
despite a significant improvement, the ratio of ineffectively treated patients was still 
considerable during the follow-up. Our results draw attention to the importance of 
hemorheological parameters as important risk factors of ischemic heart diseases and 
show the necessity of a more vigorous and guided antiplatelet therapy in the 
secondary prevention.
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